[Pj-017] Japanese Poster Session 017

[Pj-017-1] Compliance and persistence with ofatumumab treatment with RMS in clinical trials for up to 4 years [Encore Presentation]

Seika Inoue¹, Enrique Alvarez², Carrie M. Hersh³, Derrick Robertson⁴, Ayan Das Gupta⁵, Xixi Hu⁶, Ronald Zielman⁷, Ibolya Boer⁸, Andy Cheadle⁶, Jeffrey A. Cohen⁹ (1.Novartis Pharma K.K., Japan, 2.University of Colorado School of Medicine, Aurora, CO, USA, 3.Cleveland Clinic Mellen Program for MS, Lou Ruvo Center for Brain Health, Las Vegas, NV, USA, 4.Multiple Sclerosis Division, Department of Neurology, University of South Florida, Tampa, FL, USA, 5.Novartis Healthcare Pvt. Ltd., Hyderabad, India, 6.Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 7.Novartis Pharma B.V., Amsterdam, Netherlands, 8.Novartis Pharma AG, Basel, Switzerland, 9.Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA)